Tag Archive for: Dr. Alfred Hansel

MEDICA and COMPAMED 2019

MEDICA 2019oncgnostics GmbH

From 18 to 21 November we attended MEDICA 2019, in Düsseldorf. We were at the joint booth for the industry association medways e.V. in the world’s largest trade fair for the medical sector.

Record Number of Exhibitors and Visitors

This year the trade fair broke its own record once again with around 5,500 exhibitors and 121,000 visitors. About 170 different countries gathered at the No. 1 platform for international business. Many visitors came by oncgnostics’ booth to learn about our latest developments.

“For us, MEDICA is the most important trade fair of the year. This is where the industry comes together, where we make and maintain important contacts. As exhibitors, we are able to introduce ourselves, and we are very happy to use our own booth for meetings. At the same time, it is always worth taking a tour around the fair to get up to date,” says Dr Alfred Hansel, oncgnostics’ Managing Director, describing his impressions.

Pitch at COMPAMED

Dr. Peter Haug

Simultaneously to MEDICA, COMPAMED, the trade fair for medical suppliers, took place. Our Head of Business Development & Licensing, Dr Peter Haug, accepted the invitation of IVAM, the professional association for microtechnology, and gave a sales pitch at the High-tech for Medical Devices forum.

“Oncgnostics GmbH is not only a manufacturer of reliable and innovative devices for cancer diagnostics: It is also of interest as a development partner to other pharmaceutical and diagnostic companies that would like to develop reliable tests based on epigenetic markers for new indications with us. Moreover, thanks to our strategic partnership with GeneoDx, a subsidiary of the Chinese SINOPHARM Group, we are also able to offer high-volume orders,” summarises Dr Peter Haug.

/by

Oncgnostics Expands Business Relations in Asia

The oncgnostics managers together with Geneo Dx managers and colleagues.

Approval for cervical cancer screening test in the Chinese market expected in early 2020 / First contacts in Japan

Shanghai/Yokohama/Tokyo/Jena, 1 November 2019 –Our business partner in China, GeneoDx, is about to get approval to commercialise GynTect in the Chinese market. This issue was discussed at a business meeting with representatives from oncgnostics GmbH in Shanghai.

Our Chinese business partner GeneoDx, a SINOPHARM subsidiary, presented oncgnostics’ managing directors, Dr Martina Schmitz and Dr Alfred Hansel, in Shanghai with the results of their recently completed approval study for the National Medical Products Administration (NMPA) for the molecular biological test GynTect. The approval of GynTect for the Chinese market is expected in early 2020. The test allows reliable and rapid diagnosis of cervical cancer and its precancerous stages.

‘Our partners have conducted a study with approximately 1,300 samples. Results look very promising. We are optimistic that GeneoDx will receive approval for GynTect without any problems. Moreover, the study will be followed by high-ranking publications,’ states oncgnostics’ managing director Martina Schmitz.

Dr Alfred Hansel visited BioJapan in Yokohama, Japan. At the conference, he cultivated existing contacts, which he had made during a visit to MedTech Japan in Tokyo earlier this year. He also held discussions with other companies on the marketing opportunities of GynTect in Japan and other countries in Southeast Asia.

The Asian market is interesting for oncgnostics not only with regard to GynTect. International partnerships are also being sought for current pipeline projects, in particular the development of assays in the field of head and neck tumour diagnostics.

About oncgnostics:

Jena’s oncgnostics GmbH specialises in the early detection of cancer. Its tests detect changes that are characteristic of cancer cells’ DNA. Founded in 2012, the company launched GynTect in 2015. As part of its programme for the early detection of cervical cancer, the test clarifies whether cervical cancer or precancerous lesions are already present. In April 2017, GeneoDx and oncgnostics signed an exclusive license agreement for GynTect in China, Hong Kong, and Macau.

Oncgnostics GmbH is also conducting research into tests for the clarification of other types of cancer. Detailed information is available at www.oncgnostics.com.

About GynTect:

GynTect is a molecular biological test that identifies six areas of the human genome that are methylated only during the development of cancer cells. Thus, GynTect recognises malignant changes in patients.

/by

Expert Lecture in Spain

Dr. Alfred Hansel in Spanien

On 12 June, the conference ‘XIII Jornada de Formación en Patología del Tracto Genital inferior y Colposcopia‘ was held in Madrid. Oncgnostics’ managing director Dr Alfred Hansel was one of the speakers at the training event for gynaecologists.

Experts Exchange Knowledge

At the conference, experts updated their knowledge on HPV-related cancers in women’s genital tract. In his lecture, Dr Alfred Hansel described possible cervical cancer diagnostics that go beyond HPV testing. In addition, the participants were able to join various workshops, such as colposcopy courses. Furthermore, the participants had the opportunity to visit the NIMGenetics, distributor of GynTect® in Spain, booth at the industrial exhibition event, and inform themselves about the test.

/by

Surprise at Investor Days Thüringen

Investor Days

On 18 June oncgnostics managing director, Dr Alfred Hansel, visited Investor Days Thüringen in Erfurt, and was pleased to receive the ‘bm|t sustainable business award’.

Thuringia’s Sector Network Meeting

As a large sector network meeting, Investor Days bring together the different parties involved: Young companies, investors, decision makers and representatives from economy, science and politics. Selected formats and an entertaining evening programme encourage visitors to get to know each other and exchange knowledge.

Meet the Rising Stars

During the so-called ‘Meet the Rising Stars’, Oncgnostics GmbH presented itself. Managing Director Dr Alfred Hansel presented the current developments of the company to the audience in a 7-minute pitch.

The surprise of the day was the awarding of the ‘bm|t sustainable business award’ to oncgnostics GmbH: ‘We are delighted to receive this award,’ says Dr Alfred Hansel, ‘especially since we did not expect it at all. Thank you very much!’

About Investor Days

The Investor Days Thüringen is an initiative of the Foundation for Technology, Innovation and Research Thuringia (STIFT) and the beteiligungsmanagement thüringen gmbh (bm|t) to bring together innovative start-ups and growth companies with potential cooperation or business partners, as well as investors and business angels.

/by